When the first visit to the rheumatologist is established rheumatoid arthritis
Publication date: Available online 27 January 2020Source: Best Practice &Research Clinical RheumatologyAuthor(s): Peter C. Taylor, Shing T. LawAbstractThe outlook for people living with rheumatoid arthritis (RA) has improved tremendously in a generation. Major contributions to this include recognition of the importance of early treatment initiation, improved understanding of the pathobiology, the identification of therapeutic targets and their subsequent validation in clinic trials and the realisation of the importance of ‘tight control’ of inflammatory responses. Despite these advances, many patients meeting classification criteria present for the first time to a rheumatologist with longstanding symptoms. There is no definition as to when RA becomes ‘established’. But there is evidence that a ‘window of opportunity’ exists over about 12–16 weeks symptom duration, during which treatment intervention gives rise to the most optimal outcomes. This review addresses issues regarding the management of patients presenting outside the window of opportunity in terms of heterogeneity of presentation, assessment, therapeutic goals and treatment options as well as the importance of a multidisciplinary approach to holistic care.
Conclusion: ART may reduce the risk of NCIs in HIV-infected patients in general. Further research to investigate NCIs on specific antiretroviral regimens and comorbidities may provide insights regarding the long-term clinical care of these patients.
Initial data from clinical trials testing whether patients with severe coronavirus illness can be helped by a rheumatoid arthritis drug sold by Regeneron Pharmaceuticals Inc and Sanofi SA may come as early as next week, Regeneron's chief scientific officer told Reuters.
Condition: Rheumatoid Arthritis (RA) Intervention: Sponsor: AbbVie Not yet recruiting
Authors: Wiese MD, Manning-Bennett AT, Abuhelwa AY Abstract Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory auto-immune disease that can lead to permanent disability and deformity. Despite current treatment modalities, many patients are still unable to reach remission. Interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors are novel agents designed to suppress immune signalling pathways involved in inflammation and joint destruction in RA. Four IRAK-4 inhibitors have entered clinical trials.Areas covered: This review summarizes the current stage of development of IRAK-4 inhibitors in clini...
Authors: Li S, Liu X, Chen X, Bi L Abstract As the spectrum of diseases keeps changing and life pace keeps going faster, the probability and frequency of diseases caused by human inflammatory reactions also keep increasing. How to develop effective anti-inflammatory drugs has become the hotspot of researches. It has been found that alkaloids from Chinese medical herbs have anti-inflammatory, analgesic, antitumor, anticonvulsant, diuretic, and antiarrhythmic effects, among which the anti-inflammatory effect is very prominent and commonly used in the treatment of rheumatoid arthritis, ankylosing spondylitis, and othe...
In conclusion, this study demonstrated that WB could effectively alleviate disease progression of CIA mice by decreasing the IL-1β, IL-6, and TNF-α levels, modulating the OPG/RANKL system, and inhibiting the activation of NF-κB. PMID: 32256633 [PubMed]
There is paucity of data on the outcomes of acute myocardial infarction in patients with rheumatoid arthritis in the contemporary era.
The recognition that patients with rheumatoid arthritis are at a heightened risk of cardiovascular disease (CVD) events and mortality spans more than 2 decades, yet there continues to be debate as to who should screen this population for CVD risk. There are several challenges to regular screening of this population: limited time, the assumption that this problem is being addressed by the rheumatologist, and lack of awareness by primary care providers (PCP) of increased CVD risk. A collaborative approach between PCPs and rheumatologists is necessary to address the increased CVD risk and to treat these risk factors aggressively.
Planta Med DOI: 10.1055/a-1143-8521Considering the different untoward effects of the drugs prescribed for the treatment of rheumatoid arthritis (RA), there has been an increasing interest in adjuvant therapies devoid of such unfavorable reactions. Although the beneficial effects of Nigella sativa (N. sativa) on RA have been established, it seems that its mechanisms of action have not still been reviewed. The present review is designed to evaluate the effects of N. sativa on RA systematically. We searched these electronic databases until April 2019: PubMed, Scopus, ISI Web of Science, Cochrane Library, Embase, Ovi...